Many of today's most celebrated drugs are designed to hit only one biological target with great precision. But a novel clinical trial aims to turn this idea on its head by using 'network pharmacology' to more effectively tackle a common neurological disorder affecting limb movement. Claire Ainsworth looks into how medicine's proverbial 'magic bullet' might soon give way to a more sophisticated arsenal.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy
Scientific Reports Open Access 08 January 2015
-
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A
Orphanet Journal of Rare Diseases Open Access 18 December 2014
-
The chemical interactome space between the human host and the genetically defined gut metabotypes
The ISME Journal Open Access 22 November 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ainsworth, C. Networking for new drugs. Nat Med 17, 1166–1168 (2011). https://doi.org/10.1038/nm1011-1166
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1011-1166
This article is cited by
-
Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy
Scientific Reports (2015)
-
VNP: Interactive Visual Network Pharmacology of Diseases, Targets, and Drugs
CPT: Pharmacometrics & Systems Pharmacology (2014)
-
Searching for the Ideal Antiepileptogenic Agent in Experimental Models: Single Treatment Versus Combinatorial Treatment Strategies
Neurotherapeutics (2014)
-
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A
Orphanet Journal of Rare Diseases (2014)
-
The chemical interactome space between the human host and the genetically defined gut metabotypes
The ISME Journal (2013)
